MINA Human

MYC Induced Nuclear Antigen Human Recombinant

Cat. No.

BT24434

Source

Escherichia Coli.

Synonyms

MYC Induced Nuclear Antigen, MINA53, MDIG, 60S Ribosomal Protein L27a Histidine Hydroxylase, Mineral Dust-Induced Gene Protein, Histone Lysine Demethylase MINA Ribosomal Oxygenase MINA, Nucleolar Protein 52, NO52, ROX, Bifunctional Lysine-Specific Demethylase And Histidyl-Hydroxylase MINA, Myc-Induced Nuclear Antigen, 53 KDa, Mineral Dust Induced Gene Protein, MYC-Induced Nuclear Antigen, EC 1.14.11.-, Bifunctional lysine-specific demethylase and histidyl-hydroxylase MINA.

Appearance

Sterile Filtered clear solution.

Purity

Greater than 90.0% as determined by SDS-PAGE.

Usage

Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Shipped with Ice Packs

In Stock

Quick Inquiry

Description

MINA Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 485 amino acids (1-465 a.a) and having a molecular mass of 54.9kDa.

MINA is fused to a 20 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Product Specs

Introduction

MYC Induced Nuclear Antigen, also known as MINA, is an enzyme with dual functionality: it acts as both a histone lysine demethylase and a ribosomal histidine hydroxylase. In its role as a histone lysine demethylase, MINA removes methyl groups from trimethylated Lysine-9 on histone H3 (H3K9me3), a modification that ultimately leads to increased expression of ribosomal RNA. As a ribosomal histidine hydroxylase, MINA catalyzes the addition of a hydroxyl group to histidine at position 39 of the 60S ribosomal protein L27a. Notably, MINA plays a crucial role in cell growth and survival. Its involvement in ribosome biogenesis, particularly in the assembly process of pre-ribosomal particles, is significant.

Description

Recombinant MINA protein, of human origin, has been produced in E. coli. It is a single, non-glycosylated polypeptide chain composed of 485 amino acids (specifically, amino acids 1 through 465) and has a molecular weight of 54.9 kDa. For purification purposes, a 20 amino acid His-tag has been added to the N-terminus of the MINA protein. The purification process involves the use of proprietary chromatographic techniques.

Physical Appearance

A clear solution that has been sterilized by filtration.

Formulation

The MINA protein solution has a concentration of 0.25 mg/ml and is prepared in a buffer solution consisting of 20mM Tris-HCl (pH 8.0), 0.15M NaCl, 10% glycerol, and 1mM DTT.

Stability

For short-term storage (up to 2-4 weeks), the solution can be kept at 4°C. For longer storage, it is recommended to freeze the solution at -20°C. To further enhance stability during long-term storage, consider adding a carrier protein like HSA or BSA (0.1%). It's crucial to avoid repeatedly freezing and thawing the solution.

Purity

Analysis by SDS-PAGE indicates a purity level exceeding 90%.

Synonyms

Source

Escherichia Coli.

Amino Acid Sequence

MGSSHHHHHH SSGLVPRGSH MPKKAKPTGS GKEEGPAPCK QMKLEAAGGP SALNFDSPSS LFESLISPIK TETFFKEFWE QKPLLIQRDD PALATYYGSL FKLTDLKSLC SRGMYYGRDV NVCRCVNGKK KVLNKDGKAH FLQLRKDFDQ KRATIQFHQP QRFKDELWRI QEKLECYFGS LVGSNVYITP AGSQGLPPHY DDVEVFILQL EGEKHWRLYH PTVPLAREYS VEAEERIGRP VHEFMLKPGD LLYFPRGTIH QADTPAGLAH STHVTISTYQ NNSWGDFLLD TISGLVFDTA KEDVELRTGI PRQLLLQVES TTVATRRLSG FLRTLADRLE GTKELLSSDM KKDFIMHRLP PYSAGDGAEL STPGGKLPRL DSVVRLQFKD HIVLTVLPDQ DQSDETQEKM VYIYHSLKNS RETHMMGNEE ETEFHGLRFP LSHLDALKQI WNSPAISVKD LKLTTDEEKE SLVLSLWTEC LIQVV.

Product Science Overview

Structure and Function

MINA53 is a nuclear protein that is induced by the MYC oncogene. It is involved in the regulation of ribosomal RNA (rRNA) transcription and processing, which is essential for ribosome biogenesis and protein synthesis. The protein contains a JmjC domain, which is characteristic of a family of proteins known as Jumonji C (JmjC) domain-containing proteins. These proteins are known to have histone demethylase activity, which plays a role in epigenetic regulation of gene expression.

Role in Cancer

The overexpression of MYC and its target genes, including MINA53, is commonly observed in various types of cancers. MYC-induced transcriptional activation of MINA53 contributes to the oncogenic functions of MYC by promoting cell growth and proliferation. Studies have shown that MINA53 is overexpressed in several cancers, including colorectal cancer, gastric cancer, and hepatocellular carcinoma. The protein’s role in promoting ribosome biogenesis and protein synthesis is believed to be a key factor in its contribution to tumorigenesis.

Therapeutic Implications

Given its role in cancer, MINA53 has been identified as a potential therapeutic target. Inhibiting the function of MINA53 could potentially disrupt the MYC-driven oncogenic processes, thereby providing a strategy for cancer treatment. Research is ongoing to develop specific inhibitors that can target MINA53 and other MYC-induced proteins to combat MYC-driven cancers.

Recombinant Production

The recombinant form of MYC Induced Nuclear Antigen (Human Recombinant) is produced using recombinant DNA technology. This involves cloning the MINA gene into an expression vector, which is then introduced into a host cell, such as E. coli or mammalian cells. The host cells express the protein, which is subsequently purified for research or therapeutic use. Recombinant MINA53 is used in various studies to understand its function, regulation, and role in cancer, as well as to develop potential therapeutic interventions.

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Product Name

Quantity&Size*

Message

MINA Human

Description

Product Specs

Product Science Overview

Quick Inquiry

Category

Service